Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Characteristics of Artificial Immunogens Containing Peptide Mimotopes of HIV-1 Epitopes Recognized by Monoclonal Antibodies 2F5 and 2G12

The paper describes construction of TBI-based recombinant proteins TBI-2F5 and TBI-2G12 that contain peptide mimotopes of HIV-1 epitopes recognized by broadly neutralizing antibodies 2F5 and 2G12, respectively. The capacity of the immunogens to induce neutralizing antibodies was evaluated. The sera of BALB/c mice immunized with recombinant proteins TBI, TBI-2F5, and TBI-2G12 neutralized HIV-1 env-pseudoviruses. Moreover, pooled serum from mice immunized with TBI-2F5 and TBI-2G12 neutralized env-pseudoviruses of HIV-1 subtype B more effectively than individual sera.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 2000;6(2):200-206.

  2. 2.

    Boutwell CL, Rolland MM, Herbeck JT, Mullins JI, Allen TM. Viral evolution and escape during acute HIV-1 infection. J. infect. Dis. 2010;202(Suppl. 2):S309-S314.

  3. 3.

    Eroshkin AM, Karginova EA, Gileva IP, Lomakin AS, Lebedev LR, Kamyinina TP, Pereboev AV, Ignat’ev GM. Design of four-helix bundle protein as a candidate for HIV vaccine. Prot. Eng. 1995;8(2):167-173.

  4. 4.

    Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, Katinger H, Stiegler G, Anderson DC, Mc-Clure HM, Ruprecht RM. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 2004;189(12):2167-2173.

  5. 5.

    Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 2010;84(3):1302-1313.

  6. 6.

    Karpenko LI, Scherbakova NS, Chikaev AN, Tumanova OY, Lebedev LR, Shalamova LA, Pyankova OG, Ryzhikov AB, Ilyichev AA. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12. Mol. Immunol. 2012;50(4):193-199.

  7. 7.

    Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999;73(5):4009-4018.

  8. 8.

    Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010;28:413-444.

  9. 9.

    Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000;6(2):207-210.

  10. 10.

    Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J. Virol. 2002;76(14):7306-7321.

  11. 11.

    Shcherbakova NS, Shcherbakov DN, Bakulina AY, Karpenko LI, Ryzhikov AB, Ilyichev AA. Artificial polyepitope HIV-1 immunogen containing mimotope of 2F5 epitope. Protein Pept. Lett. 2016;23(2):159-168.

  12. 12.

    Smith GP, Petrenko VA. Phage display. Chem. Rev. 1997;97(2): 391-410.

  13. 13.

    Xu W, Hofmann-Lehmann R, McClure HM, Ruprecht RM. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine. 2002;20(15):1956-1960.

  14. 14.

    Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 2005;79(2):1252-1261.

Download references

Author information

Correspondence to N. S. Shcherbakova.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 167, No. 2, pp. 213-217, February, 2019

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shcherbakova, N.S., Chikaev, A.N., Rudometov, A.P. et al. Characteristics of Artificial Immunogens Containing Peptide Mimotopes of HIV-1 Epitopes Recognized by Monoclonal Antibodies 2F5 and 2G12. Bull Exp Biol Med 167, 259–262 (2019). https://doi.org/10.1007/s10517-019-04504-1

Download citation

Key Words

  • HIV-1
  • monoclonal antibodies 2F5 and 2G12
  • HIV-1 immunogen
  • phage display